Advanced Non-Small Cell Lung Cancer Clinical Trials

151 clinical trials for Advanced Non-Small Cell Lung Cancer across international registries, including 29 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) — RECRUITING · PHASE1
• AMT-116 in Combination With AK112 in Patients With Lung Cancer — RECRUITING · PHASE1
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — RECRUITING · PHASE2
• A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation — RECRUITING · PHASE3
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — RECRUITING · PHASE3
• Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer — RECRUITING · PHASE1
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy — RECRUITING
• A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) — RECRUITING
• Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway — RECRUITING
• Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer — RECRUITING · PHASE1
• A PHASE 2 STUDY OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) IN COMBINATION WITH BNT116 (FIXVAC LUNG) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 ≥50%. — RECRUITING · PHASE2
• Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC — RECRUITING · PHASE1
• Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC). — RECRUITING · NA
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated — RECRUITING · PHASE3
• Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers — RECRUITING · PHASE2
• Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• SSGJ-707 in Advanced Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC — RECRUITING
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation — RECRUITING · PHASE1
• Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study — RECRUITING · PHASE2
• Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG — RECRUITING · PHASE2
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance — RECRUITING · PHASE3
• A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE AS FIRST LINE TREATMENT FOR ADVANCED NON SMAL CELL LUNG CANCER — COMPLETED · PHASE2
• A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE2
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — ACTIVE_NOT_RECRUITING · PHASE3
• Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer — TERMINATED · PHASE1
• An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE2
• AZD9291 in Combination With Ascending Doses of Novel Therapeutics — ACTIVE_NOT_RECRUITING · PHASE1
• Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients — NOT_YET_RECRUITING · PHASE2
• Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation — OTHER
• A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) — ACTIVE_NOT_RECRUITING · PHASE2
• A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation — TERMINATED · PHASE3
• A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE2 — TERMINATED · PHASE2
• A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE2
• A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) — COMPLETED · PHASE2
• Study With Various Immunotherapy Treatments in Participants With Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE2
• Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients — ACTIVE_NOT_RECRUITING
• Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC — NOT_YET_RECRUITING · PHASE2
• A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) — ACTIVE_NOT_RECRUITING · PHASE2
• A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50% — TERMINATED · PHASE3
• AZD9291 First Time In Patients Ascending Dose Study — COMPLETED · PHASE1

Refine this search